[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605109":3},{"organization":4,"outcomesModule":7,"designInfo":55,"detailedDescription":11,"studyPopulation":11,"armGroups":66,"interventions":77,"overallOfficials":88,"centralContacts":92,"locations":100,"responsibleParty":320,"collaborators":11,"id":322,"slug":323,"hasResults":324,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":324,"sex":330,"minAge":331,"maxAge":332,"enrollmentInfo":333,"targetDuration":11,"studyType":336,"phases":337,"briefSummary":339,"conditions":340,"keywords":11,"overallStatus":103,"whyStopped":11,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":351},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants With Clinical Remission at Week 52",null,"At Week 52",[14,17,20,23,25,27,29,32,34,37,39,41,43,45,47,49,52],{"measure":15,"description":11,"timeFrame":16},"Change From Baseline in Pediatric Ulcerative Colitis Activity Index (PUCAI) Response","From Baseline, at Week 12",{"measure":18,"description":11,"timeFrame":19},"Percentage of Participants With PUCAI Remission","At Week 12",{"measure":21,"description":11,"timeFrame":22},"Change From Baseline in Tummy Ulcerative Colitis (TUMMY-UC) Scores","From Baseline to Week 12",{"measure":24,"description":11,"timeFrame":19},"Partial Modified Mayo Score (pmMS)",{"measure":26,"description":11,"timeFrame":19},"Percentage of Participants With Symptomatic Response",{"measure":28,"description":11,"timeFrame":19},"Percentage of Participants With Symptomatic Remission",{"measure":30,"description":11,"timeFrame":31},"Change From Baseline in PUCAI Response at Week 52","From Baseline, at Week 52",{"measure":33,"description":11,"timeFrame":12},"Percentage of Participants With PUCAI Remission at Week 52",{"measure":35,"description":11,"timeFrame":36},"Change From Baseline in TUMMY-UC Scores","From Baseline to Week 52",{"measure":38,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Remission",{"measure":40,"description":11,"timeFrame":12},"Percentage of Participants With Endoscopic Improvement",{"measure":42,"description":11,"timeFrame":12},"Percentage of Participants With Histologic Improvement",{"measure":44,"description":11,"timeFrame":12},"Percentage of Participants With Histologic-endoscopic Mucosal Improvement",{"measure":46,"description":11,"timeFrame":12},"Percentage of Participants With Histologic-endoscopic Mucosal Remission",{"measure":48,"description":11,"timeFrame":12},"Percentage of Participants With Clinical Remission Without the use of Corticosteroids",{"measure":50,"description":11,"timeFrame":51},"Percentage of Participants With Adverse Events (AEs)","From Baseline up to approximately 4 years",{"measure":53,"description":11,"timeFrame":54},"Serum Concentration of Afimkibart","Up to approximately 4 years",{"allocation":56,"interventionModel":57,"interventionModelDescription":11,"primaryPurpose":58,"observationalModel":11,"timePerspective":11,"maskingInfo":59},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":60,"maskingDescription":11,"whoMasked":61},"QUADRUPLE",[62,63,64,65],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[67,73],{"label":68,"type":69,"description":70,"interventionNames":71},"Afimkibart Dose A","EXPERIMENTAL","Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.",[72],"Drug: Afimkibart",{"label":74,"type":69,"description":75,"interventionNames":76},"Afimkibart Dose B","Participants will receive Afimkibart IV followed by Afimkibart SC.",[72],[78],{"type":79,"name":80,"description":81,"armGroupLabels":82,"otherNames":83},"DRUG","Afimkibart","Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.",[68,74],[84,85,86,87],"PF-06480605","RVT-3101","RG6631","RO7790121",[89],{"name":90,"affiliation":5,"role":91},"Clinical Trials","STUDY_DIRECTOR",[93,98],{"name":94,"role":95,"phone":96,"phoneExt":11,"email":97},"Reference Study ID Number: CA45905 https:\u002F\u002Fforpatients.roche.com\u002F No attachments to email below.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":99,"role":95,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[101,115,125,135,145,153,165,175,185,197,205,217,229,238,249,258,269,280,286,291,302,311],{"facility":102,"status":103,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":114,"contacts":11},"Children's Hospital Colorado","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":110,"coordinates":111},"Point",[112,113],-104.83192,39.72943,{"lat":113,"lon":112},{"facility":116,"status":103,"city":117,"state":118,"zip":119,"country":107,"countryCode":108,"cosmosGeoPoint":120,"geoPoint":124,"contacts":11},"University of South Florida","Tampa","Florida","33612",{"type":110,"coordinates":121},[122,123],-82.45843,27.94752,{"lat":123,"lon":122},{"facility":126,"status":103,"city":127,"state":128,"zip":129,"country":107,"countryCode":108,"cosmosGeoPoint":130,"geoPoint":134,"contacts":11},"Children's Healthcare of Atlanta","Atlanta","Georgia","30342",{"type":110,"coordinates":131},[132,133],-84.38798,33.749,{"lat":133,"lon":132},{"facility":136,"status":103,"city":137,"state":138,"zip":139,"country":107,"countryCode":108,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"Northwell Health","Lake Success","New York","11042",{"type":110,"coordinates":141},[142,143],-73.71763,40.77066,{"lat":143,"lon":142},{"facility":146,"status":103,"city":138,"state":138,"zip":147,"country":107,"countryCode":108,"cosmosGeoPoint":148,"geoPoint":152,"contacts":11},"NYU Langone Health","10016",{"type":110,"coordinates":149},[150,151],-74.00597,40.71427,{"lat":151,"lon":150},{"facility":154,"status":103,"city":155,"state":156,"zip":157,"country":158,"countryCode":159,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"Mater Hospital Brisbane","South Brisbane","Queensland","4101","Australia","AU",{"type":110,"coordinates":161},[162,163],153.02049,-27.48034,{"lat":163,"lon":162},{"facility":166,"status":103,"city":167,"state":168,"zip":169,"country":158,"countryCode":159,"cosmosGeoPoint":170,"geoPoint":174,"contacts":11},"Royal Childrens Hospital","Parkville","Victoria","3052",{"type":110,"coordinates":171},[172,173],144.95,-37.78333,{"lat":173,"lon":172},{"facility":176,"status":103,"city":177,"state":178,"zip":179,"country":158,"countryCode":159,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"Perth Children's Hospital","Nedlands","Western Australia","6009",{"type":110,"coordinates":181},[182,183],115.8073,-31.98184,{"lat":183,"lon":182},{"facility":186,"status":103,"city":187,"state":188,"zip":189,"country":190,"countryCode":191,"cosmosGeoPoint":192,"geoPoint":196,"contacts":11},"CECIP - Centro de Estudos Clínicos do Interior Paulista","Jaú","São Paulo","17201-130","Brazil","BR",{"type":110,"coordinates":193},[194,195],-48.55778,-22.29639,{"lat":195,"lon":194},{"facility":198,"status":103,"city":188,"state":188,"zip":199,"country":190,"countryCode":191,"cosmosGeoPoint":200,"geoPoint":204,"contacts":11},"BR Trials - Pesquisa Clínica","03325-050",{"type":110,"coordinates":201},[202,203],-46.63611,-23.5475,{"lat":203,"lon":202},{"facility":206,"status":103,"city":207,"state":208,"zip":209,"country":210,"countryCode":211,"cosmosGeoPoint":212,"geoPoint":216,"contacts":11},"Hospital For Sick Children","Toronto","Ontario","M5G 1X8","Canada","CA",{"type":110,"coordinates":213},[214,215],-79.39864,43.70643,{"lat":215,"lon":214},{"facility":218,"status":103,"city":219,"state":220,"zip":221,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":11},"Children's Hospital ZheJiang University School of Medicine","Hangzhou","Zhejiang","310052","China","CN",{"type":110,"coordinates":225},[226,227],120.16142,30.29365,{"lat":227,"lon":226},{"facility":230,"status":103,"city":231,"state":11,"zip":232,"country":222,"countryCode":223,"cosmosGeoPoint":233,"geoPoint":237,"contacts":11},"Ruijin Hospital Shanghai Jiaotong University School of Medicine","Shanghai","200025",{"type":110,"coordinates":234},[235,236],121.45806,31.22222,{"lat":236,"lon":235},{"facility":239,"status":103,"city":240,"state":11,"zip":241,"country":242,"countryCode":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":11},"IATROS International","Bloemfontein","9301","South Africa","ZA",{"type":110,"coordinates":245},[246,247],26.214,-29.12107,{"lat":247,"lon":246},{"facility":250,"status":103,"city":251,"state":11,"zip":252,"country":242,"countryCode":243,"cosmosGeoPoint":253,"geoPoint":257,"contacts":11},"Emmed Research","Pretoria","0002",{"type":110,"coordinates":254},[255,256],28.18783,-25.74486,{"lat":256,"lon":255},{"facility":259,"status":103,"city":260,"state":11,"zip":261,"country":262,"countryCode":263,"cosmosGeoPoint":264,"geoPoint":268,"contacts":11},"National Taiwan University Hospital","Taipei","100","Taiwan","TW",{"type":110,"coordinates":265},[266,267],121.52639,25.05306,{"lat":267,"lon":266},{"facility":270,"status":103,"city":271,"state":11,"zip":272,"country":273,"countryCode":274,"cosmosGeoPoint":275,"geoPoint":279,"contacts":11},"Chulalongkorn University","Bangkok","10330","Thailand","TH",{"type":110,"coordinates":276},[277,278],100.50144,13.75398,{"lat":278,"lon":277},{"facility":281,"status":103,"city":271,"state":11,"zip":282,"country":273,"countryCode":274,"cosmosGeoPoint":283,"geoPoint":285,"contacts":11},"Siriraj Hospital","10700",{"type":110,"coordinates":284},[277,278],{"lat":278,"lon":277},{"facility":287,"status":103,"city":271,"state":11,"zip":11,"country":273,"countryCode":274,"cosmosGeoPoint":288,"geoPoint":290,"contacts":11},"Ramathibodi Hospital",{"type":110,"coordinates":289},[277,278],{"lat":278,"lon":277},{"facility":292,"status":103,"city":293,"state":11,"zip":294,"country":295,"countryCode":296,"cosmosGeoPoint":297,"geoPoint":301,"contacts":11},"Birmingham Children's Hospital","Birmingham","B4 6NH","United Kingdom","UK",{"type":110,"coordinates":298},[299,300],-1.89983,52.48142,{"lat":300,"lon":299},{"facility":303,"status":103,"city":304,"state":11,"zip":305,"country":295,"countryCode":296,"cosmosGeoPoint":306,"geoPoint":310,"contacts":11},"Addenbrooke's Hospital","Cambridge","CB2 0QQ",{"type":110,"coordinates":307},[308,309],0.11667,52.2,{"lat":309,"lon":308},{"facility":312,"status":103,"city":313,"state":11,"zip":314,"country":295,"countryCode":296,"cosmosGeoPoint":315,"geoPoint":319,"contacts":11},"Sheffield Childrens Hospital","Sheffield","S10 2TH",{"type":110,"coordinates":316},[317,318],-1.4659,53.38297,{"lat":318,"lon":317},{"type":321,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605109","phase-3-a-study-to-evaluate-the-pharmacokinetics-safety-and-efficacy-of-afimkibart-ro7790121-in-children-with-moderately-to-severely-active-ulcerative-colitis-100605109",false,"NCT07158242","A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis","A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis","AMETRINE-PEDS","Inclusion Criteria:\n\n* Bodyweight \\>= 10 kilogram (kg)\n* Confirmed diagnosis of UC\n* Moderately to severely active UC, defined as modified Mayo Score (mMS) or 5 to 9 points, including endoscopic score of 2 or 3, confirmed by centrally read endoscopy (flexible sigmoidoscopy or colonoscopy)\n* Demonstrated intolerance or inadequate response (IR) to one or more of the following categories of drugs: systemic corticosteroids, immunomodulators, and\u002For biologic therapies as outlined in the protocol\n\nExclusion Criteria:\n\n* Monogenic disorder pertaining to infant onset inflammatory bowel disease (IBD)\n* Current diagnosis of Crohn's disease (CD), abdominal\u002Fintrabdominal\u002Fperianal fistula and\u002For abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease\n* Presence of an ostomy or ileoanal pouch\n* Current diagnosis or suspicion of primary sclerosing cholangitis\n* Any major surgery within 6 weeks prior to screening or a major planned surgery during the study\n* Active tuberculosis (TB) infection suggested by positive TB testing, clinical symptoms, and\u002For chest imaging (X-ray or CT)","ALL","2 Years","17 Years",{"count":334,"type":335},100,"ESTIMATED","INTERVENTIONAL",[338],"PHASE3","This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).",[341],"Moderately to Severely Active Ulcerative Colitis","2026-09-02",{"date":344,"type":345},"2026-09-08","ACTUAL",{"date":347,"type":345},"2026-04-15",{"date":349,"type":335},"2031-03-31",{"name":5,"class":6},22]